Literature DB >> 26346631

Subacute Hemolysis in Sickle Cell Mice Causes Priapism Secondary to NO Imbalance and PDE5 Dysregulation.

Nikolai A Sopko1, Hotaka Matsui1, Johanna L Hannan1, Dan Berkowitz2, Hunter C Champion3, Lewis L Hsu4, Biljana Musicki1, Arthur L Burnett1, Trinity J Bivalacqua1.   

Abstract

INTRODUCTION: Recent research suggests that priapism in sickle cell disease (SCD) is due to dysregulation of penile erection homeostasis including alteration of nitric oxide synthase (NOS) and phosphodiesterase type 5 (PDE5) activities by excessive levels of reactive oxygen species (ROS) released during hemolysis. It is unknown if subacute exposure to hemolysis is sufficient or if chronic reconditioning of erectile tissues is required for perturbation of homeostatic pathways and whether PDE5 inhibitor (PDE5I) treatment can restore erectile homeostasis in the subacute setting. AIMS: The aim of this study was to investigate the effects of subacute hemolysis (3-month exposure) on priapism and NO pathway regulation.
METHODS: Mice underwent bone marrow transplantation with either SCD (BM-SS) or wild-type (WT) bone marrow. BM-SS mice were treated with sildenafil 100 mg/kg/day. We measured intracavernous pressure (ICP) measurements with or without cavernous nerve stimulation following bone marrow transplantation to assess for priapism. MAIN OUTCOME MEASURES: ICP and frequency of erections were assessed. Penile tissues were analyzed for NOS, protein kinase G (PKG), PDE5, and ROS activities.
RESULTS: BM-SS mice demonstrated a priapism phenotype. PDE5I treatment reduced the frequency of erections in BM-SS mice (1.7 ± 1.1 vs. 5.5 ± 2.8 erections per hour, P < 0.05). Penile tissues from BM-SS mice demonstrated decreased NOS, PKG, PDE5 and elevated ROS activities compared with that of control mice. PDE5I treatment increased NOS (11.6 ± 1.3% vs. 7.8 ± 2.3%, P < 0.05) and PDE5 (76.3 ± 9.8% vs. 52.3 ± 11.1%, P < 0.05) activities and decreased ROS activity (137.8 ± 12.1% vs. 199.1 ± 11.3%, P < 0.05) compared with non-PDE5I treated BM-SS mice. PKG activity was increased beyond control levels with PDE5I treatment (158.4 ± 10.3%, P < 0.05).
CONCLUSION: Short-term hemolysis is sufficient to establish a priapism phenotype and results in loss of erectile function. PDE5I treatment ameliorates priapism, in part, because of restored NO balance with decreased ROS generation and increased PDE5 activity.
© 2015 International Society for Sexual Medicine.

Entities:  

Keywords:  Endothelial Nitric Oxide Synthase; PDE5 Inhibitor; Phosphodiesterase 5; Priapism; Reactive Oxygen Species; Sickle Cell Disease

Mesh:

Substances:

Year:  2015        PMID: 26346631      PMCID: PMC4600325          DOI: 10.1111/jsm.12976

Source DB:  PubMed          Journal:  J Sex Med        ISSN: 1743-6095            Impact factor:   3.802


  31 in total

1.  Randomized controlled trial of sildenafil for preventing recurrent ischemic priapism in sickle cell disease.

Authors:  Arthur L Burnett; Uzoma A Anele; Irene N Trueheart; John J Strouse; James F Casella
Journal:  Am J Med       Date:  2014-03-25       Impact factor: 4.965

2.  Oxygen radical inhibition of nitric oxide-dependent vascular function in sickle cell disease.

Authors:  M Aslan; T M Ryan; B Adler; T M Townes; D A Parks; J A Thompson; A Tousson; M T Gladwin; R P Patel; M M Tarpey; I Batinic-Haberle; C R White; B A Freeman
Journal:  Proc Natl Acad Sci U S A       Date:  2001-12-18       Impact factor: 11.205

3.  Identification and regulation of human PDE5A gene promoter.

Authors:  C S Lin; S Chow; A Lau; R Tu; T F Lue
Journal:  Biochem Biophys Res Commun       Date:  2001-01-26       Impact factor: 3.575

4.  Inhibition of Rho-kinase improves erectile function, increases nitric oxide signaling and decreases penile apoptosis in a rat model of cavernous nerve injury.

Authors:  Johanna L Hannan; Maarten Albersen; Omer Kutlu; Christian Gratzke; Christian G Stief; Arthur L Burnett; Jeffrey J Lysiak; Petter Hedlund; Trinity J Bivalacqua
Journal:  J Urol       Date:  2012-09-25       Impact factor: 7.450

5.  Excess adenosine A2B receptor signaling contributes to priapism through HIF-1α mediated reduction of PDE5 gene expression.

Authors:  Chen Ning; Jiaming Wen; Yujin Zhang; Yingbo Dai; Wei Wang; Weiru Zhang; Lin Qi; Almut Grenz; Holger K Eltzschig; Michael R Blackburn; Rodney E Kellems; Yang Xia
Journal:  FASEB J       Date:  2014-03-10       Impact factor: 5.191

6.  Pathology of Berkeley sickle cell mice: similarities and differences with human sickle cell disease.

Authors:  Elizabeth A Manci; Cheryl A Hillery; Carol A Bodian; Zheng G Zhang; Gerard A Lutty; Barry S Coller
Journal:  Blood       Date:  2005-09-15       Impact factor: 22.113

7.  Long-term oral phosphodiesterase 5 inhibitor therapy alleviates recurrent priapism.

Authors:  Arthur L Burnett; Trinity J Bivalacqua; Hunter C Champion; Biljana Musicki
Journal:  Urology       Date:  2006-05       Impact factor: 2.649

8.  Opiorphin is a master regulator of the hypoxic response in corporal smooth muscle cells.

Authors:  Shibo Fu; Moses Tarndie Tar; Arnold Melman; Kelvin Paul Davies
Journal:  FASEB J       Date:  2014-05-06       Impact factor: 5.191

9.  Increased cavernosal relaxations in sickle cell mice priapism are associated with alterations in the NO-cGMP signaling pathway.

Authors:  Mário Angelo Claudino; Carla Fernanda Franco-Penteado; Marcus Alexandre Finzi Corat; Ana Paula Gimenes; Luiz Augusto Correa Passos; Edson Antunes; Fernando Ferreira Costa
Journal:  J Sex Med       Date:  2009-06-02       Impact factor: 3.802

10.  Sildenafil citrate-restored eNOS and PDE5 regulation in sickle cell mouse penis prevents priapism via control of oxidative/nitrosative stress.

Authors:  Trinity J Bivalacqua; Biljana Musicki; Lewis L Hsu; Dan E Berkowitz; Hunter C Champion; Arthur L Burnett
Journal:  PLoS One       Date:  2013-07-02       Impact factor: 3.240

View more
  6 in total

1.  Resolution of Acute Priapism in Two Children With Sickle Cell Disease Who Received Nitrous Oxide.

Authors:  Michael H Greenwald; Colleen K Gutman; Claudia R Morris
Journal:  Acad Emerg Med       Date:  2019-08-01       Impact factor: 3.451

2.  Testosterone replacement in transgenic sickle cell mice controls priapic activity and upregulates PDE5 expression and eNOS activity in the penis.

Authors:  B Musicki; S Karakus; W Akakpo; F H Silva; J Liu; H Chen; B R Zirkin; A L Burnett
Journal:  Andrology       Date:  2017-11-16       Impact factor: 3.842

Review 3.  What is the effectiveness of surgical and non-surgical therapies in the treatment of ischemic priapism in patients with sickle cell disease? A systematic review by the EAU Sexual and Reproductive Health Guidelines Panel.

Authors:  S Minhas; A Salonia; M Gül; B Luca; K Dimitropoulos; P Capogrosso; U Milenkovic; A Cocci; R Veeratterapillay; G Hatzichristodoulou; V Modgil; G I Russo; T Tharakan; A Kalkanli; M I Omar; C Bettocchi; J Carvalho; G Corona; T H Jones; A Kadioglu; J I Martinez-Salamanca; E C Serefoglu; P Verze
Journal:  Int J Impot Res       Date:  2022-08-08       Impact factor: 2.408

Review 4.  Testosterone Deficiency in Sickle Cell Disease: Recognition and Remediation.

Authors:  Biljana Musicki; Arthur L Burnett
Journal:  Front Endocrinol (Lausanne)       Date:  2022-05-03       Impact factor: 6.055

Review 5.  Advances in the understanding of priapism.

Authors:  Matthew Hudnall; Amanda B Reed-Maldonado; Tom F Lue
Journal:  Transl Androl Urol       Date:  2017-04

6.  Caspase-3 dependent nitrergic neuronal apoptosis following cavernous nerve injury is mediated via RhoA and ROCK activation in major pelvic ganglion.

Authors:  Johanna L Hannan; Hotaka Matsui; Nikolai A Sopko; Xiaopu Liu; Emmanuel Weyne; Maarten Albersen; Joseph W Watson; Ahmet Hoke; Arthur L Burnett; Trinity J Bivalacqua
Journal:  Sci Rep       Date:  2016-07-08       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.